Hartnup disorder is an autosomal recessive disorder caused by mutations in the *SLC6A19* gene, which encodes the main epithelial neutral amino acid transporter B^0^AT1.[@bib1], [@bib2] This disorder is characterized by neutral aminoaciduria due to impaired amino acid transport in kidney proximal tubule epithelial cells, whereas the extent of intestinal transport impairment appears to be less consistent. Various other clinical symptoms such as pellagra-like rash, cerebellar ataxia, or other neurologic dysfunctions may be present in affected individuals, while other subjects remain, besides experiencing aminoaciduria, asymptomatic. Phenotypic variability might be partially explained by the differential impact of various mutations and the frequent compound heterozygosity.

Differential phenotypic effects of mutations could arise from differential interactions of B^0^AT1 with tissue-specific modulatory and/or associated proteins. We and others have previously shown that B^0^AT1 requires association with collectrin for luminal surface expression in the kidney proximal tubule, whereas collectrin is nearly absent in the small intestine, the other major site of B^0^AT1 expression.[@bib3], [@bib4] Intriguingly, the closest homologue of collectrin is the angiotensin-converting enzyme (ACE) 2, which functions as a key carboxypeptidase enzyme in the renin-angiotensin system. ACE2 is involved in heart and kidney pathologies[@bib5] and has been identified as the severe acute respiratory syndrome receptor in vitro[@bib6] and in vivo.[@bib7] Importantly, previous studies have reported ACE2 expression and severe acute respiratory syndrome/coronavirus replication in human small intestine.[@bib8], [@bib9]

We first investigated whether ACE2 associates with B^0^AT1 in mouse small intestine. Immunofluorescence, coimmunoprecipitation, and functional data presented here clearly show that ACE2 is the specific partner of B^0^AT1 in the small intestine and thus that the accessory protein of B^0^AT1 is tissue specific.

We then tested the influence of collectrin and ACE2 on the function of human B^0^AT1 Hartnup disorder--causing mutations in the *Xenopus laevis* oocyte expression system. Our results suggest that specific defects in interaction with tissue-specific accessory proteins may lead to differential defects in intestinal versus kidney (re)absorption of neutral amino acids and thereby participate in the variability of phenotypes observed in subjects with Hartnup disorder.

Materials and Methods {#sec1}
=====================

Animals {#sec1.1}
-------

The *ace2* and *collectrin* wild-type and knockout mice were housed in standard conditions and fed a standard diet. Generation of the knockout mice was described elsewhere.[@bib3], [@bib5] Animals were either anesthetized and perfused with a fixative solution for localization studies or killed to remove small intestine and kidneys. Scraped small intestine mucosa cells and total kidneys were frozen in liquid nitrogen for subsequent RNA extraction or brush border membrane vesicle preparation. All procedures for mice handling were according to the Swiss Animal Welfare laws and approved by the Kantonales Veterinäramt Zürich.

Organ Fixation {#sec1.2}
--------------

Male mice were anesthetized with ketamine and xylazine (90 mg/kg body wt, Narketan 10; Vétoquinol, Lure, France) and xylazine (10 mg/kg body wt, Xylazin; Streuli, Uznach, Switzerland) intraperitoneally and perfused through the left cardiac ventricle with phosphate-buffered saline (PBS; phosphate buffer, pH 7.4) followed by a buffered paraformaldehyde solution (4%, pH 7) as previously described.[@bib10] Small intestine was then harvested, incubated overnight in paraformaldehyde solution, washed several times with PBS, and stored in PBS/0.02% sodium azide at 4°C. Tissues were then mounted with Kryostat OCT (Medite, Nunningen, Switzerland), frozen in liquid propane, and stored at --80°C.

Immunofluorescence {#sec1.3}
------------------

Immunofluorescence was performed as previously described.[@bib11] Primary antibodies were diluted (1:200) for rabbit affinity purified anti-mouse B^0^AT1[@bib11] and diluted (1:100) for affinity purified goat anti-mouse ACE2 (R&D Systems, Minneapolis, MN). Secondary antibodies were diluted (1:500) for Alexa Fluor 488 donkey anti-goat immunoglobulin (Ig) G and Alexa Fluor 594 donkey anti-rabbit IgG (Molecular Probes/Invitrogen, Carlsbad, CA). Digital images were viewed by using a Nikon Eclipse TE300 epifluorescence microscope (Nikon Instruments Inc, Melville, NY) equipped with a DS-5M Standard charge-coupled device camera (Nikon Instruments Inc) and acquired with NIS-Elements (Nikon Instruments Inc).

Brush Border Membrane Preparations {#sec1.4}
----------------------------------

Brush border membrane vesicles were prepared from small intestine mucosa cells and kidneys using the Mg^2+^ precipitation technique as described elsewhere.[@bib12]

Western Blotting {#sec1.5}
----------------

Western blotting was performed as previously described.[@bib11] Primary antibodies were diluted to 1:1000 goat affinity purified anti-mouse ACE2 (R&D Systems), 1:1000 goat affinity purified anti-human ACE2 (R&D Systems), 1:2000 or 1:1000 rabbit affinity purified anti-mouse or anti-human B^0^AT1, respectively[@bib11] (Pineda, Berlin, Germany), and 1:10,000 for mouse anti-mouse β-actin (Sigma, St Louis, MO). Secondary antibodies were diluted (1:5000) for enhanced chemiluminescence anti-rabbit or anti-goat IgG horseradish peroxidase linked fragment from donkey or mouse, respectively (Amersham Biosciences, Piscataway, NJ, and Pierce, Rockford, IL) or anti-mouse IgG alkaline phosphatase conjugate from mouse (Promega, Madison, WI). Antibody binding was detected with Immobilon Western Chemiluminescent HRP or AP substrate (Millipore, Billerica, MA) and chemiluminescence visualized with a DIANA III camera (Raytest, Dietikon, Switzerland).

Intestinal Ring Uptake {#sec1.6}
----------------------

Uptake of radiolabeled [l]{.smallcaps}-isoleucine was performed as previously described[@bib13] on ileum segments, with slight modifications. Briefly, everted ileum segments were incubated in bubbling (Oxycarbon) Krebs-Tris buffer (pH 7.4) containing 1 mmol/L [l]{.smallcaps}-isoleucine (1 μCi ^14^C-L-Ile/mL) for 5 minutes at 37°C. Ileum segments were dried at 55°C O/N on cellulose (Sartorius AG, Goettingen, Germany) and weighed. Segments were then lysed in 0.75N NaOH for 6 hours and neutralized with 10N HCl, and the radioactivity was determined by liquid scintillation. Na^+^ was replaced by *N*-methyl-[d]{.smallcaps}-glucamine in the condition without Na^+^. Amino acid transport was expressed relative to dry tissue weight.

Identification of New Hartnup Mutations {#sec1.7}
---------------------------------------

After informed consent was obtained, genomic DNA was obtained from whole blood of patients with Hartnup disorder as previously described.[@bib1] Intronic primers to sequence exons and splice sites of each exon were chosen. Primer sequences are available on request. Polymerase chain reaction products of each exon were separated by electrophoresis on agarose gels and specific bands removed for DNA isolation. This DNA was sequenced in both directions using a Beckman Coulter CEQ8000 (Beckman Coulter, Fullerton, CA) following the manufacturer\'s protocol. The absence of each recognized missense mutation was confirmed in 100 ethnically matched control alleles.

Isolation and Subcloning of Complementary DNAs and Site-Directed Mutagenesis {#sec1.8}
----------------------------------------------------------------------------

Human B^0^AT1, ACE2, and collectrin complementary DNAs (cDNAs) were amplified from human kidney Marathon-Ready cDNA (Clontech, Mountain View, CA) by polymerase chain reaction using a proofreading polymerase (Pfu; Promega). The primers used are available on request. The amplified ACE2 and collectrin cDNAs were subcloned in pcDNA3 and mouse ACE2 and collectrin in pcDNA 3.1 hygromycin (Invitrogen). The B^0^AT1 was subcloned into a pBlueScript modified *Xenopus laevis* expression vector containing both the 5′ and 3′ ends of the β-globin gene (KSM) kindly provided by Dr Leila Virkki. For expression in *X laevis* oocytes, the plasmids were linearized and used as template for RNA synthesis (mMESSAGEmMACHINE; Ambion, Austin, TX). The mutation in human B^0^AT1 and ACE2 was performed using the QuikChange Site-Directed Mutagenesis Kit according to the manufacturer (Stratagene, La Jolla, CA). The mutation ACE2-R273Q was shown previously to be catalytically inactive but normally expressed.[@bib14] The B^0^AT1 mutations were performed on the single nucleotide polymorphism (SNP) V252I, which has been shown to behave like the wild type.

Homology Model {#sec1.9}
--------------

The homology model of human B^0^AT1 transport was based on the crystal structure of LeuT*Aa* (NP_214423) as a template using the I-TASSER server.[@bib15], [@bib16] The pdb file was visualized using Pymol (DeLano Scientific LLC, Palo Alto, CA).

Transport Studies in X laevis Oocytes {#sec1.10}
-------------------------------------

Expression studies and influx assays using radiolabeled amino acid tracer were performed in *X laevis* oocytes after 5 to 9 days of expression, as described previously.[@bib17] Data are expressed as pmol · h^−1^  · oocyte^−1^, and values obtained for noninjected oocytes are subtracted.

Electrophysiology Using 2-Microelectrode Voltage Clamp {#sec1.11}
------------------------------------------------------

The 2-microelectrode voltage clamp (TEVC) technique was used for the recording of whole cell currents from *X laevis* oocytes. Recordings were performed at room temperature 5 to 9 days after injection with complementary RNA. Recordings were performed as previously described[@bib16] at a membrane holding potential of −50 mV. To control for batch variation in transporter expression and measured current, the data from the selectivity experiment were normalized to *I~L-Ile\ 10\ mmol/L~*. Pooled data are shown as mean ± SEM where n represents the number of pooled cells. Experimental protocols were repeated at least twice. Nonlinear regression calculations were performed using GraphPad Prism version 4.0 (GraphPad Inc, San Diego, CA).

Labeling of Surface Proteins in Xenopus Oocytes {#sec1.12}
-----------------------------------------------

Surface labeling of oocytes expressing human B^0^AT1 alone or coexpressed with mouse ACE2 or human collectrin was performed using 2-(aminoethyl)-methanethiosulfonate-biotin (Sigma-Aldrich, Buchs, Switzerland) as previously described.[@bib18] Samples were separated on a 10% sodium dodecyl sulfate gel and immunoblotted with affinity purified rabbit anti-human B^0^AT1 antibody (Pineda). Signal intensity was quantified with the AIDA Image Analyzer (Raytest).

Immunoprecipitations {#sec1.13}
--------------------

### Mouse brush border membrane proteins {#sec1.13.1}

Brush border membrane vesicles were incubated with serum anti-B^0^AT1 polyclonal antibody[@bib11] in EBC solution (20 mmol/L Tris-HCl, pH 8.0, 120 mmol/L NaCl, 0.5% Nonidet P40) at 4°C on a rotator. The immunocomplexes were coupled to Immobilized Protein A/G beads (Pierce) O/N at 4°C on a rotator. The beads were washed with NET-N solution (20 mmol/L Tris-HCl, pH 8.0, 100 mmol/L NaCl, 0.5% Nonidet P40, 1 mmol/L EDTA), and the immunoprecipitate was loaded on a polyacrylamide gel. Western blot was performed as described previously with anti-mouse B^0^AT1 antibody to check for B^0^AT1 immunoprecipitation or anti-mouse ACE2 antibody to test ACE2 coimmunoprecipitation. To avoid background staining, protein A/G coupled to alkaline phosphatase was used as a secondary antibody (Pierce).

### *X laevis* oocytes {#sec1.13.2}

Immunoprecipitation of human B^0^AT1, B^0^AT1 mutants, and human ACE2 was performed as previously described.[@bib19] Briefly, oocytes were lysed in EBC buffer (as described for brush border membrane vesicles) and the supernatant was first incubated with serum anti-human B^0^AT1 and subsequently with Immobilized Protein A/G beads (Pierce) O/N at 4°C on a rotator. Western blot was performed as described previously to test for human ACE2 coimmunoprecipitation.

Statistics {#sec1.14}
----------

Data are presented as means ± SEM. Analyses were performed by running the GraphPad Prism 4.0 software (GraphPad). Between-group comparisons were performed by Student unpaired *t* test. Multiple comparisons within groups were performed by repeated-measures one-way analysis of variance, followed by Tukey posttest. Statistical significance was accepted at *P \<* .05.

Results {#sec2}
=======

ACE2 Is the Intestinal Partner of the Amino Acid Transporter B^0^AT1 {#sec2.1}
--------------------------------------------------------------------

We first assessed the potential in vivo role of ACE2 as intestinal B^0^AT1 associated protein by investigating the B^0^AT1 expression in *ace2*-null mice.[@bib5] Remarkably, B^0^AT1 protein was completely absent in small intestine brush border membranes of mice lacking ACE2 ([Figure 1](#fig1){ref-type="fig"} *A* and *B*), whereas it was normally expressed in kidney ([Figure 1](#fig1){ref-type="fig"} *B*). This organ distribution of B^0^AT1 in *ace2*-null mice mirrors the situation observed in *collectrin*-null mice, where B^0^AT1 is absent in kidney and, as shown in this study, normally expressed in small intestine ([Figure 1](#fig1){ref-type="fig"} *B*). Furthermore, ACE2 was coimmunoprecipitated with B^0^AT1 from intestinal brush border membranes of wild-type mice, demonstrating in vivo interaction ([Figure 1](#fig1){ref-type="fig"} *C*).Figure 1ACE2 and B^0^AT1 colocalization and functional interaction. (*A*) Immunofluorescence analysis shows that B^0^AT1 protein expression is lost in small intestine of *ace2*-null mice. Small intestine sections from *ace2*^+/y^ and *ace2*^−/y^ were colabeled with antibodies against ACE2 (*green*) and B^0^AT1 (*red*) and additionally viewed by phase contrast (PC). (*B*) Western blot analysis shows that B^0^AT1 is absent in small intestine but present in kidney brush border membranes of *ace2*-null mice, whereas B^0^AT1 is expressed in small intestine and absent from kidney brush border membranes in *collectrin*-null mice. The loading of brush border membranes (2.5--20 μg) was tested using a β-actin antibody (βA). Note that male *ace2*^+/y^ or *ace2*^−/y^ and female *ace2*^+/+^ or *ace2*^−/−^ mice were used with similar results. (*C*) Coimmunoprecipitation shows interaction of ACE2 with B^0^AT1 in mouse small intestine. Complexes were immunoprecipitated (IP) from small intestine brush border membrane vesicles (BBMVs) using anti-B^0^AT1 antibody (AB) and analyzed by Western blot (WB) using anti-mouse ACE2 antibody. (*D*) Na^+^-dependent uptake of [l]{.smallcaps}-isoleucine (L-Ile) is abolished in ileum segments from *ace2*^−/y^ mice. The transport was measured in the presence (*white bar*) and in the absence (*black bar*) of sodium. Data points represent mean values of 4 intestinal ring uptakes from independent experiments ± SEM, \*\*\**P* \< .001. ns, not significant.

The function of B^0^AT1 was also shown to depend on ACE2 in mouse intestine. We observed that the lack of B^0^AT1 protein expression in the intestine of *ace2^−/y^* mice abolished the Na^+^-dependant portion of [l]{.smallcaps}-isoleucine transport measured in intestinal rings ([Figure 1](#fig1){ref-type="fig"} *D*). The total (in the presence of Na^+^) but not the sodium-independent transport was dramatically reduced when compared with the wild-type littermates. The equivalent effect was previously shown in kidney brush border membrane vesicles of *collectrin* ^−/−^ mice, where the transport was also reduced.[@bib3] These data show that ACE2 is essential for expression and function of B^0^AT1 in intestine, whereas collectrin controls B^0^AT1 expression in the kidney.

ACE2 and Collectrin Increase the Function of Human Hartnup Transporter B^0^AT1 In Vitro {#sec2.2}
---------------------------------------------------------------------------------------

The tissue-specific associated proteins collectrin and ACE2 expressed in *X laevis* oocytes mimicked their effect in vivo on B^0^AT1 by stimulating its transport function. Expressed alone in oocytes, human B^0^AT1 induced a low amino acid transport rate as shown by us and others previously.[@bib1], [@bib2] We show here that its coexpression with mouse or human ACE2 or human collectrin increases the transport function ∼10-fold ([Supplementary Figure 1](#fige1){ref-type="fig"} *A*; see supplemental material online at [www.gastrojournal.org](http://www.gastrojournal.org)). The mouse orthologue of collectrin did not activate human B^0^AT1, although it has been shown to be effective on mouse B^0^AT1.[@bib3] We have as yet no explanation for this differential impact of the collectrin orthologues in the *X laevis* expression system. Different from collectrin, ACE2 has one catalytic site. It is a carboxypeptidase and converts angiotensin I and II to angiotensin 1--9 and 1--7, respectively,[@bib20], [@bib21] functionally antagonizing its homologue ACE. We analyzed the role of the catalytic activity of ACE2 in the functional interaction with B^0^AT1 ([Supplementary Figure 1](#fige1){ref-type="fig"} *B*; see supplemental material online at [www.gastrojournal.org](http://www.gastrojournal.org)). The catalytically dead mutant (ACE2 R273Q)[@bib14] was as efficient as the wild type in enhancing B^0^AT1 function, suggesting that it is not necessary for the interaction. This was expected because human collectrin shares 48% identity with ACE2 at the level of its carboxyl-terminal membrane anchor region but entirely lacks the extracellular peptidase domain.[@bib22]

The amino acid selectivity, ion dependence, and kinetic characteristics of human B^0^AT1 coexpressed with ACE2 are, besides a much higher maximal transport rate, very similar to those previously reported for human B^0^AT1 expressed alone[@bib1] ([Supplementary Figure 2](#fige2){ref-type="fig"} *A*--*E*; see supplemental material online at [www.gastrojournal.org](http://www.gastrojournal.org)).

Differential Interaction of Accessory Proteins With B^0^AT1 Hartnup Mutations {#sec2.3}
-----------------------------------------------------------------------------

To address the question whether Hartnup mutations impact on the interaction of B^0^AT1 with its accessory proteins ACE2 and/or collectrin, we expressed missense mutations alone or together with either accessory protein in *X laevis* oocytes and analyzed their transport function and surface expression. Besides 5 previously described missense mutations and one nonsynonymous SNP, we characterized 4 new missense mutations identified in patients with neutral aminoaciduria characteristic of Hartnup disorder belonging to 4 different families ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figure 3](#fige3){ref-type="fig"} *A*--*D*; see supplementary material online at [www.gastrojournal.org](http://www.gastrojournal.org)).[@bib1], [@bib2] The nonsynonymous SNP V252I essentially behaved as wild-type B^0^AT1 when coexpressed with collectrin and ACE2 ([Figure 2](#fig2){ref-type="fig"} *A*, *upper* and *middle panels*). Interestingly, the observed 2-fold to 3-fold increase in B^0^AT1 surface expression measured by surface biotinylation only partially explains the almost 10-fold increase in surface transport function induced by coexpression with collectrin or ACE2 ([Figure 2](#fig2){ref-type="fig"} *A*, *lower panel*, and *representative Western blot*).Table 1Missense Mutations in the *SLC6A19*/Human B^0^AT1 Gene Described in Subjects With Hartnup DisorderProteinWild typeMutationPosition from the atgPosition in the proteinR57C[@bib1]CgcTgc1691st TMSA69T[a](#tblfn1){ref-type="table-fn"}GccAcc2052nd TMSG93R[a](#tblfn1){ref-type="table-fn"}GggAgg2772nd TMSD173N[@bib2]GacAac5172nd ELR240Q[@bib2]cGacAa7193th ELL242P[@bib2]cTgcCg7253th ELP265L[a](#tblfn1){ref-type="table-fn"}cCgcTg7946th TMSE501K[@bib2]GagAag150110th TMSP579L[a](#tblfn1){ref-type="table-fn"}CcgTcg17356th EL[^1][^2]Figure 2Differential function of Hartnup mutations coexpressed with collectrin or ACE2 in *X laevis* oocytes. Wild-type and mutant human B^0^AT1 are shown in this figure as 3 groups with different functional characteristics and labeled *A*--*C*. (*A*) The transport function and the surface expression of both wild-type and nonsynonymous SNP V252I of B^0^AT1 are increased by coexpression with human collectrin or mouse ACE2. (*B*) The relatively low transport activity of B^0^AT1 D173N and P265L mutants expressed alone is increased by coexpression with ACE2 but not with collectrin. The surface expression of the D173N mutant is also significantly increased by coexpression with ACE2. (*C*) The wild-type--like function of the A69T or R240Q mutants expressed alone is not increased in the presence of collectrin or ACE2, although in the case of A69T its surface expression is increased. The upper panels of *A*--*C* show the transport function measured as radiolabeled [l]{.smallcaps}-isoleucine (L-Ile) uptake (means ± SEM of 13--31 oocytes from 3 independent experiments), and the middle panel shows the transport function as current measured by TEVC (9--11 oocytes from 3 batches). \**P* \< .05, \*\*\**P* \< .001. The lower panels show the surface expression assayed by Western blot using surface-biotinylated proteins and a representative Western blot. The data correspond to the means ± SEM (n = 3--5 independent experiments) of the results normalized to the value obtained for B^0^AT1 expressed alone. For the transport experiments, the significance was evaluated using analysis of variance with Tukey posttest and for the surface biotinylation the comparison of means was performed by unpaired *t* test. (*D*) B^0^AT1 and the mutants D173N, P265L, R240Q, and A69T interact with ACE2 in *X laevis* oocytes. The transporters expressed alone or together with human ACE2 were immunoprecipitated (IP) from oocyte lysates using anti-human B^0^AT1 antibody and complexes were analyzed by Western blot (WB) using anti-human ACE2 antibody. NI, noninjected.

Surprisingly, collectrin and ACE2 coexpression differentially impacted on the surface expression and function of the 2 B^0^AT1 mutants D173N and P265L ([Figure 2](#fig2){ref-type="fig"} *B*). In both cases, coexpression with ACE2 increased the transport rate whereas coexpression with collectrin either had the opposite effect or no effect ([Figure 2](#fig2){ref-type="fig"} *B*, *upper panel*). The transport function of these mutants was shown to be Na^+^ dependent as for wild-type B^0^AT1 ([Figure 3](#fig3){ref-type="fig"}, *upper* and *middle panels*). Surface biotinylation experiments suggested that the differential function of these B^0^AT1 mutants with the 2 associated proteins is due, in the case of D173N, to a difference in surface expression, whereas the surface expression appeared in the case of P265L to be similar to both associated proteins ([Figure 2](#fig2){ref-type="fig"} *B*, *lower panel*, and *representative Western blot*). Finally, the mutants D173N and P265L coprecipitated with human ACE2, confirming that they interact with ACE2 ([Figure 2](#fig2){ref-type="fig"} *D*).Figure 3The ion dependency of D173N, P265L, A69T, and R240Q coexpressed with ACE2 or collectrin is not altered; transport is Na^+^ but not Cl^−^ dependent. Wild-type human B^0^AT1 (WT) and the mutants D173N, P265L, A69T, and R240Q were expressed alone or with human collectrin or mouse ACE2. The ion dependence was tested by substituting Na^+^ with *N*-methyl-[d]{.smallcaps}-glucamine (NMDG) and substituting Cl^−^ with gluconate. Function was assayed by influx of radiolabeled [l]{.smallcaps}-isoleucine (L-Ile). For each mutation, 3 independent experiments (15--24 oocytes) were pooled. Comparison of means was performed by analysis of variance with Tukey as posttest. Data represent means ± SEM. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001. ns, not significant.

We next analyzed the 2 B^0^AT1 mutations A69T and R240Q that, when expressed alone, display the same [l]{.smallcaps}-isoleucine transport function and ion dependence as wild-type B^0^AT1, whereas their transport function was not activated in the presence of either associated protein ([Figure 2](#fig2){ref-type="fig"} *C*, *upper* and *middle panels*, and [Figure 3](#fig3){ref-type="fig"}, *lower panel*). In the case of the newly described A69T, this was particularly surprising, because its surface expression was increased 2-fold to 3-fold by coexpression with both accessory proteins ([Figure 2](#fig2){ref-type="fig"} *C*, *lower panel*, and *representative Western blot*) and its interaction with ACE2 confirmed by coimmunoprecipitation ([Figure 2](#fig2){ref-type="fig"} *D*). In contrast, the surface expression of R240Q did not appear to be increased by the presence of the accessory proteins ([Figure 2](#fig2){ref-type="fig"} *C*, *lower panel*, and *representative Western blot*), although the mutant transporter was coimmunoprecipitated with human ACE2 to some extent ([Figure 2](#fig2){ref-type="fig"} *D*).

The mutations R57C, L242P, and E501K have previously been tested by expression in *X laevis* oocytes and showed no transport capacity.[@bib1], [@bib2] Coexpression of these mutants with collectrin and ACE2 did not change their impaired function and did not affect their cell surface expression ([Figure 4](#fig4){ref-type="fig"}). Similarly, the newly described mutations G93R and P579L lack function also in the presence of associated proteins. However, the surface expression of G93R was selectively increased by ACE2 ([Figure 4](#fig4){ref-type="fig"}, *lower panel*, and *representative Western blot*).Figure 4The B^0^AT1 mutants R57C, G93R, L242P, E501K, and P579L exhibit no transport activity when expressed alone or coexpressed with collectrin or ACE2. Function was assayed by influx of radiolabeled [l]{.smallcaps}-isoleucine (L-Ile) (*upper panels*) or TEVC (*middle panels*). For each mutant, 3 independent experiments (13--31 oocytes for influx and 9--11 for TEVC) were pooled. Comparison of means was performed by analysis of variance with Tukey as posttest. Data represent means ± SEM. ns, not significant. Cell surface expression of labeled proteins (*lower panels*) was analyzed by Western blot. The bands were quantified and data normalized to the values obtained from oocytes expressing B^0^AT1 proteins alone. For each mutation, 3 to 4 independent experiments were pooled. Comparison of means was performed by unpaired *t* test. Data represent means ± SEM. \**P* \< .05. ns, not significant.

Discussion {#sec3}
==========

We recently reported that collectrin (Tmem27) associates with and controls the expression of B^0^AT1 in the kidney proximal tubule.[@bib3], [@bib4] In this study, we showed a novel and unexpected function of the important renin-angiotensin system enzyme ACE2 that associates with the luminal amino acid transporter B^0^AT1 in small intestine and thereby controls its surface expression and function. B^0^AT1 associates in a tissue-specific manner with ACE2 in small intestine and with collectrin in the kidney. Thus, *ace*2- and *collectrin*-null mice can be used to study the role of the neutral amino acid transporter B^0^AT1 in kidney and intestine independently.

The same effect was observed on human B^0^AT1 orthologue expressed in the heterologous expression systems, *X laevis* oocytes. The coexpression of the 2 accessory proteins, ACE2 or collectrin, increased the transport rate and the cell surface expression of the transporter. The analysis of the function and surface expression of B^0^AT1/Hartnup disorder--causing mutations expressed alone or together with the 2 partner proteins allowed us to discriminate classes of mutants that might differentially impact on the phenotype of the patients.

The Hartnup disorder--causing mutations in B^0^AT1 are localized throughout the protein, as shown on the homology model depicted in [Figure 5](#fig5){ref-type="fig"}. This is also the case for the largest class of mutations mentioned here, the "dead" mutants, 3 of which were reported earlier (R57C, L242P, and E501K[@bib1], [@bib2]) and 2 of which are newly described here (G93R and P579L) ([Supplementary Figure 3](#fige3){ref-type="fig"} *C* and *D*; see supplemental material online at [www.gastrojournal.org](http://www.gastrojournal.org)). These mutants do not display any measurable function, which is consistent with the fact that, with one exception, they do not reach the plasma membrane neither when expressed alone nor upon coexpression with associated proteins.Figure 5Missense mutations in the *SLC6A19* gene causing Hartnup disorder. The model of B^0^AT1 is based on the Slc6 bacterial homologue from *Aquifex aeolicus* LeuT~*Aa*~[@bib16] and the transmembrane segments are numbered. The localization of mutations causing a loss of surface expression (R57, G93, L242, E501, P579) is depicted in the *left panel*. The sites of mutations leading to a differential interaction with the 2 accessory proteins (D173 and P265) are depicted as *black spheres* on the *middle panel*, and the sites of the mutations preventing both accessory proteins of stimulating the transport function are depicted on the *right panel* (A69 and R240).

The second class of mutants corresponds to those that, expressed alone, function as wild-type B^0^AT1 but are not stimulated by either associated protein. In the case of R240Q, its surface expression is not increased upon coexpression with ACE2 or collectrin, but coimmunoprecipitation demonstrates that its interaction with ACE2 is not abolished. Assuming a qualitative effect of the R240Q mutation on this interaction, our observation is nonetheless potentially compatible with the hypothesis recently put forward by the group of Broer, namely that the localization of this mutation at the surface of B^0^AT1 might impact on the interaction with accessory proteins.[@bib23] Further studies are necessary to clarify the mechanism by which this mutation, initially classified as an SNP, prevents the normal activation of B^0^AT1 by the accessory proteins. In contrast, in the case of the other functional mutant of this class A69T, an increase in cell surface expression of this mutant B^0^AT1 was demonstrated upon interaction with the associated proteins ([Figure 2](#fig2){ref-type="fig"} *C* and *D*). One possible explanation of why the increase in surface expression did not lead to an increase in transport rate is that ACE2/A69T-B^0^AT1 heterodimers reaching the cell surface remain inactive, meaning that the associated protein inhibits the function of A69T-B^0^AT1. The fact that the residue mutated in A69T is part of a highly conserved motif (NGGG*A*F) shown to undergo conformational changes during the transport cycle is compatible with this hypothesis.[@bib24] Additionally, that the coexpression of ACE2 or collectrin apparently activates the transport rate of wild-type B^0^AT1 several-fold more than it increases its surface expression (∼10-fold vs ∼2.5-fold) also suggests that associated proteins may impact on transporter function, although normally by increasing the cycling rate.

The most intriguing class of mutants in regard to its potential phenotypic impact is represented by D173N and the newly described P265L. These mutants differentially interact with the 2 tissue-specific accessory proteins such that their function is stimulated only by the intestine-specific associated protein ACE2. Interestingly, the D173N allele is relatively frequent in unrelated Hartnup pedigrees and can also be observed in healthy white patients with a high heterozygote frequency (1:122 healthy individuals).[@bib2], [@bib25] We know of no potential selective advantage for heterozygous carriers that explains the persistence and geographic spread of this mutant allele.[@bib26], [@bib27] The selective functional interaction of D173N with the intestinal accessory protein ACE2 might prevent deleterious effects due to a lack of amino acid absorption and thereby allowing the "survival" of this frequent allele. Although as yet no evidence of genotype-phenotype relationship performed in patients were reported, studies performed long before the identification of the Hartnup transporter have shown that intestinal amino acid absorption differs between subjects with Hartnup disorder.[@bib28], [@bib29]

Taken together, our data show that the expression and function of the main epithelial amino acid transporter are modulated by tissue-specific accessory proteins. Moreover, the intriguing fact that these accessory proteins can interact differentially with Hartnup mutations and thereby differentially affect kidney and intestinal amino acid transport function suggests that collectrin and ACE2 may also contribute significantly to the phenotypic heterogeneity among individuals with Hartnup disorder.

Supplementary data {#sec5}
==================

Supplementary Figure 1Function of human B^0^AT1 coexpressed with orthologues of collectrin and ACE2 in *X laevis* oocytes. (*A*) Coexpression of ACE2 or human collectrin increases B^0^AT1 function in *X laevis* oocytes. Tracer flux experiments (*upper graph*, n = 16--32) and TEVC (*lower graph*, n = 11) show that human B^0^AT1 (hB^0^AT1) coexpressed with human ACE2 (hACE2), mouse ACE2 (mACE2), or human collectrin (hColl) transports [l]{.smallcaps}-isoleucine more efficiently than when expressed alone or in combination with mouse collectrin (mColl). Data points represent means ± SEM. \*\*\**P* \< .001. ns, not significant. (*B*) Human B^0^AT1 function is increased by coexpressed human ACE2 independent of its protease activity. The protease-dead human ACE2 mutant (ACE2 R273Q) stimulated the human B^0^AT1-mediated [l]{.smallcaps}-isoleucine influx to the same extent as wild-type human ACE2. Data points represent means ± SEM (n = 15--16). ns, not significant.Supplementary Figure 2Functional characterization of the complex formed by human B^0^AT1 and ACE2 in *X laevis* oocytes. (*A*) The amino acid transport by human B^0^AT1 coexpressed with mouse ACE2 in *X laevis* oocytes is Na^+^ but not Cl^−^ dependent. The ion dependence was tested by substituting Na^+^ by *N*-methyl-[d]{.smallcaps}-glucamine (NMDG) or Li^+^ and Cl^−^ by gluconate in the superfusion solution used for TEVC. The values were normalized to the current obtained by superfusion of the oocytes with 10 mmol/L [l]{.smallcaps}-isoleucine in solution containing Na^+^ and Cl^−^ (*I*~norm~). Comparison of means was performed by analysis of variance with Tukey as posttest. Each data point represents the mean ± SEM (n = 16). \*\*\**P* \< .001. (*B*) Amino acid transport by human B^0^AT1 coexpressed with mouse ACE2 in *X laevis* oocytes is maximal at neutral pH. The pH dependence of the transport was measured by TEVC in oocytes clamped at --50 mV and superfused with Na^+^ solution buffered at pH 5.5, 6.5, 7.4, or 8.0. Values were normalized to the current obtained by superfusion of oocytes with 10 mmol/L [l]{.smallcaps}-isoleucine in solution pH 7.4 (*I*~norm~). Comparison of means was performed by analysis of variance with Tukey as posttest. Each data point represents the mean ± SEM (n = 9). \**P* \< .05, \*\**P* \< .01. (*C*--*E*) Human B^0^AT1 coexpressed with ACE2 transports a broad range of neutral amino acids with low affinity. (*C*) The substrate selectivity of human B^0^AT1 coexpressed with mouse ACE2 was measured by TEVC in oocytes clamped at --50 mV and superfused with Na^+^ solution containing 1 mmol/L (*white bars*) or 10 mmol/L (*black bars*) of amino acids. The currents induced by the amino acids were normalized to the currents obtained in oocytes perfused with 10 mmol/L [l]{.smallcaps}-isoleucine (*I*~norm~). Data are shown as mean values ± SEM (n = 8--11) and the amino acids are indicated in single letter code. (*D* and *E*) The K~*0.5*~ and V~*max*~ for [l]{.smallcaps}-isoleucine and Na^+^ of human B^0^AT1 coexpressed with mouse ACE2 was estimated using TEVC. For the Na^+^ concentration dependence experiments, the cells were first equilibrated with the indicated Na^+^ concentration (0, 1, 5, 10, 30, 50, 70, and 100 mmol/L) before the perfusate containing [l]{.smallcaps}-isoleucine (10 mmol/L) was applied. For the [l]{.smallcaps}-isoleucine concentration dependence experiments, the cells were perfused with increasing concentrations of [l]{.smallcaps}-isoleucine (0.1, 0.3, 1, 3, and 10 mmol/L). The continuous line is the nonlinear regression fit of the Michaelis--Menten equation to the data. Each data point represents the mean ± SEM (*C*, n = 26--27; *D*, n = 10--22).Supplementary Figure 3Pedigrees of 4 families with new Hartnup disorder mutations. (*A*) Danish pedigree: 2 of 3 siblings were compound heterozygous for P265L and L242P. The symptoms observed were quite diverse between the 2 sisters. The younger one was diagnosed with Hartnup disorder in early childhood due to pellagra-like skin rash and an atactic gait that improved with administration of niacin.[@fr1] The older affected sibling never showed skin pathologies or ataxia. (*B*) Another Danish pedigree, where the only child affected was a compound heterozygous for A69T and the original Hartnup mutation IVS8+2T→G. This patient was the first child of unrelated parents and was diagnosed at 1 year of age after a suspected seizure prompted a metabolic screening of urine. Plasma amino acids and electroencephalography were normal. The patient subsequently had normal growth and development without epilepsy, ataxia, or pellagra. (*C*) The other Danish patient was a compound heterozygous for P579L and the original Hartnup mutation IVS8+2T→G. This patient was the second child of unrelated parents and was diagnosed at 2 years of age after onset of partial complex epilepsy with great difficulty to control seizures. The patient had normal plasma amino acids and never had ataxia or pellagra. (*D*) Another patient from a German family was diagnosed as homozygous for the new missense mutation G93R. This patient was diagnosed at 6 years of age during a migraine workup and also never had ataxia or pellagra. The affected subjects are depicted as *filled symbols*.
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[^1]: TMS, transmembrane segment; EL, extracellular loop.

[^2]: New mutations identified in this study. The previously published mutations by Kleta et al[@bib1] and Seow et al[@bib2] are also listed. R240Q was initially described as SNP by Seow et al.[@bib2]
